A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Sponsor: Merck Sharp & Dohme LLC
ClinicalTrials ID:NCT06818643
This clinical trial investigates the safety and tolerability of MK-3120, administered via IV infusion, in participants with advanced solid tumors unresponsive to existing treatments. Eligible participants may include those with controlled HIV, undetectable HBV after antiviral therapy, or undetectable HCV. The study aims to explore new therapeutic options for these challenging cancer cases.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Eligibility Criteria
Inclusion Criteria
- Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments
- If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)
- If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
- If hepatitis C virus (HCV) infected, must have undetectable HCV viral load
Exclusion Criteria
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
- Has uncontrolled significant cardiovascular disease or cerebrovascular disease
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
- Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
- Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 2 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active infection requiring systemic therapy, with exceptions
- History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has HBV or HCV infection
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| The University of Alabama at Birmingham ( Site 1005) | 35249 | Birmingham | Alabama |
| University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003) | 33136 | Miami | Florida |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009) | 07601 | Hackensack | New Jersey |
| Virginia Commonwealth University ( Site 1008) | 23219 | Richmond | Virginia |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.